[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arterial-stiffness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arterial-stiffness":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,50,86,108,142,185,221,252,279,307,337,372,400,423,450,474,501,525,555,577,612,635,660,683,707],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100444826","natural-history-study-of-cadasil-100444826",false,"NCT05072483","Natural History Study of CADASIL","* INCLUSION CRITERIA:\n\nEligibility for this study may be determined based on information collected under other NHLBI-approved protocols, outside records and patient report.\n\nIn order to be eligible to participate in this study, an individual must meet criteria 1 \\& 2 and either criteria 3 or 4:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Male or female, aged 18 to 100 years (inclusive).\n3. Established diagnosis of CADASIL or NOTCH3 mutations, as determined by genetic testing.\n4. Healthy controls.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnancy at time of consent.\n2. Subjects who lack capacity to consent and don't have a legally authorized representative.\n3. Subjects who decline to provide samples for blood and\u002For tissue studies.\n4. Subjects who do not speak English.\n5. Subjects whose scans or examinations show unexpected brain conditions (outside of CADASIL) which would interfere with interpretation of testing.\n6. Subjects unable to undergo an MRI scan or subjects meeting the following criteria:\n\n   * Subjects who have internal non-MRI compatible metals (i.e., cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain or on blood vessels, cochlear implants, artificial heart valves or metal fragments in the eye) as these rendering an MRI unsafe\n   * Subjects with ferromagnetic dental bridges or crowns (exclusion only for 7.0T)\n   * Subjects unable to remain supine for the expected length of the MRI (i.e., up to 1 hour)\n   * Subjects with uncontrolled head movements\n   * Subjects who are claustrophobic for the expected length of the MRI (i.e., up to 1 hour) and claustrophobia cannot be controlled with anti-anxiety medication.",true,"ALL","18 Years","100 Years",{"count":21,"type":22},155,"ESTIMATED","OBSERVATIONAL","Background:\n\nCADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a genetic disorder. It causes narrowing of the small blood vessels and can lead to strokes and dementia. Researchers want to monitor people with CADASIL over time.\n\nObjective:\n\nTo learn more about how CADASIL affects a person s blood vessels over time.\n\nEligibility:\n\nAdults ages 18 and older who have CADASIL, and healthy volunteers.\n\nDesign:\n\nParticipants will be screened with a medical record review.\n\nParticipants will have 4 study visits over 9 years. Visits will last 6 8 hours per day, for 2 4 days.\n\nParticipants will give blood and urine samples. They will have an electrocardiogram to record their heart s electrical activity. They will fill out a family tree. They will have tests that measure mental abilities like memory and attention. They may have a skin biopsy. They may have a lumbar puncture.\n\nParticipants will have an eye exam. Their pupils will be dilated. They will receive a dye via intravenous (IV) line. Pictures will be taken of their eyes.\n\nParticipants will have an imaging scan of their brain. They may receive a contrast agent via IV.\n\nParticipants blood flow and blood vessel flexibility will be measured. In one test, a probe will be pressed against the skin of the their wrist, neck, and groin. In another test, they will hold one arm still while a microscope makes videos of the blood flow through a fingernail. In another test, they will perform light exercise or other activities while wearing an elastic band around their head or probes placed on their arm or leg.\n\nHealthy volunteers will complete some of the above tests.",[26,27,28,29,30],"Cardiovascular Disease","Arterial Stiffness","Germline Mutation in the NOTCH 3 Gene","Pathogenesis of CADASIL","Clinical Phenotype of CADASIL",[32,33,34,35,36],"Biospecimen Procurement","Laboratory Research Specimens","progressive chronic hypoperfusion","Stroke","progressive white matter degeneration, and debilitating dementia.","RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":41},"2022-04-18",{"date":45,"type":22},"2041-06-01",{"name":47,"class":48},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":49},"100639968","cf-pwv-and-tyg-index-study-100639968","NCT07589374","Cf-PWV and TyG Index Study","Correlation Between Carotid-Femoral Pulse Wave Velocity and Triglyceride-Glucose Index and Its Derived Metrics","RIGID-TyG","Inclusion Criteria:\n\n* Adults aged 18 to 65 years;\n* Both sexes;\n* Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation;\n* Not receiving antihypertensive medication at the time of assessment;\n* Availability of valid 24-hour ABPM data;\n* Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement;\n* Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index;\n* Ability and willingness to provide written informed consent (for prospectively recruited participants).\n\nExclusion Criteria:\n\n* Use of antihypertensive medication at the time of evaluation;\n* Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements;\n* Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings;\n* Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements;\n* Presence of severe vascular disease or conditions affecting arterial waveform assessment;\n* Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis;\n* Pregnancy;\n* Refusal or inability to provide informed consent (for prospectively recruited participants).","65 Years",{"count":60,"type":22},800,"This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease.\n\nArterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk.\n\nAt the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk.\n\nAnother important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack.\n\nThis study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods.\n\nNo additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.",[63,64,27,65,66],"Hypertension","Insulin Resistance Syndrome","Cardiovascular Risk","Blood Pressure Variability",[68,69,70,71,72,73,74,75],"Arterial stiffness","Pulse wave velocity","Triglyceride-glucose index","Insulin resistance","Ambulatory blood pressure monitoring","Morning blood pressure surge","Blood pressure variability","Cardiovascular risk","NOT_YET_RECRUITING","2026-05-19",{"date":79,"type":41},"2026-05-22",{"date":38,"type":22},{"date":82,"type":22},"2028-07-01",{"name":84,"class":85},"Hospital de Base","OTHER",{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100580386","carotid-femoral-oscillometric-and-estimated-pulse-wave-velocity-100580386","NCT06836622","Carotid-Femoral, Oscillometric and Estimated Pulse Wave Velocity","Correlation Between the Values of Carotid-Femoral, Oscillometric and Estimated Pulse Wave Velocity","CF-O-E-PWV","Inclusion Criteria :\n\n\\- Individuals older than 18 with an elevated office blood pressure :\n\n* suspected hypertension diagnosis or\n* uncontrolled hypertension under treatment\n\nExclusion Criteria:\n\n24-hour ABPM recordings presenting:\n\n* less than 70% of the expected measurements or\n* fewer than 20 valid awake or seven valid sleeping measurements or\n* fewer than two valid daytime and one valid night-time measurement per hour",{"count":95,"type":22},350,"What is the purpose of this research? This research aims to compare three different methods of measuring pulse wave velocity, which is the main parameter used for assessing arterial stiffness. This parameter is as important as blood pressure in predicting future cardiovascular risk.\n\nThe investigators intend to compare carotid-femoral pulse wave velocity, which is the gold standard for measuring arterial stiffness, with brachial pulse wave velocity measured using a device similar to a blood pressure monitor and a mathematical formula validated in a large European population.\n\nWho is eligible for this survey? Anyone aged 18 or older who has been invited may participate, provided they sign an informed consent form.\n\nWhere will the field research be conducted? The research will be conducted at a health center specializing in the treatment of hypertension. This center is a reference for outpatient blood pressure monitoring in the city of Uberaba (MG), Brazil. Patients enrolled in the study will also be included in the Hypertension Center of the Faculdade de Medicina de São José do Rio Preto (FAMERP).\n\nWhich procedures will be performed by research participants? All participants who consent will answer some questions about their demographic and health information. A trained nurse will measure their weight, height, and blood pressure after a 5-minute rest, and then measure carotid-femoral pulse wave velocity. The participant will lie down on a bed and the nurse will place a sensor on the middle of their neck and the groin. The device will automatically deliver the parameters. At least three measurements are required for each participant. Measurements normally take between 10 and 15 minutes. Then, participants will wear a device to record blood pressure and pulse wave velocity for 24 hours. The nurse will fit the cuff around the participant's arm and attach the monitoring device to a belt around their waist. The device will take measurements every 20 to 30 minutes. 24 hours later, the participant must return to the research venue to have the equipment removed.\n\nWhat are the risks and adverse events of the procedures? There are no known risks or adverse events (AEs) associated with carotid-femoral pulse wave velocity measurements. The risks of this research are minimal, limited to discomfort during the AMBP recording, which occurs at a low frequency. However, excessive arm pain, allergic reactions, and edema may occur. To minimize these risks, a nurse will be available via telephone to aid all participants during the AMBP recordings.",[63,27,98,99],"Pulse Wave Analysis","Pulse Wave Velocity",[68,63,69],"2026-05-09",{"date":103,"type":41},"2026-05-13",{"date":38,"type":22},{"date":106,"type":22},"2027-12-01",{"name":84,"class":85},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":16,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":49},"100557964","prebiotic-effects-of-california-grapes-on-gut-health-and-cardiometabolic-health-in-overweight-men-and-women-100557964","NCT06544954","Prebiotic Effects of California Grapes on Gut Health and Cardiometabolic Health in Overweight Men and Women","Assessing Prebiotic Effect of California Grape Consumption on Gut Microbiome and Impact on Intestinal Permeability, Vascular Function, and Systemic Inflammation in Over-weight Subjects: Differences in Effects Between Men and Women","CALGRAM","Inclusion Criteria:\n\n* post-menopausal women (cessation of menstruation for minimum two years)\n* overweight and obese (BMI between 25-35 kg\u002Fm2)\n* stable treatment for type 2 diabetes or metabolic syndrome\n* ability to understand the intervention concept and written consent to participate\n* willingness to accept randomization, undergo testing and intervention procedures, and deliver stool and blood samples\n\nExclusion Criteria:\n\n* menopausal hormone replacement therapy started within less than 6 months\n* antibiotics, prebiotics within last 3 months\n* antidiabetic treatment involving insulin (for type 1 diabetes)\n* vegetarian\u002Fvegan and not able to follow modified diet\n* any serious medical condition including but not limited to coronary artery disease, uncontrolled hypertension, stroke, congestive heart failure, insulin-dependent diabetes, liver disease, active cancer and anemia\n* psychiatric disease that interferes with the understanding and implementation of the intervention\n* history of eating disorders such as bulimia nervosa, anorexia nervosa, severe binge eating disorder in the last 5 years\n* history of substance abuse or alcohol abuse\n* involvement in a weight loss intervention program (including anti-obesity medication) within last 3 months or have had bariatric surgery\n* current smokers (within last 180 days)\n* use of dietary supplements containing polyphenols in the past 1 month\n* strenuous exercise greater than 10 hours per week","45 Years","70 Years",{"count":119,"type":22},40,"INTERVENTIONAL",[122],"NA","The goal of this clinical trial is to assess the impact of table grape consumption on gut microbiome, intestinal permeability, systemic inflammation, and vascular function in healthy overweight men and women aged 45-70 years. The main questions it aims to answer are:\n\n* Does daily grape intake alter intestinal microbiome composition and intestinal permeability?\n* Are changes in gut microbiota and intestinal permeability correlated with changes in cardiometabolic risk factors (inflammation, vascular function, lipid profiles)?\n* Does response to grape intake on gut microbiota, intestinal permeability, cardiometabolic and inflammatory markers differ between men and women?\n* Are metabolic pathways modified by grape consumption able to explain the link between gut health and cardiometabolic factors?\n\nResearchers will compare freeze-dried grape powder to placebo powder to see if grape powder improves cardiometabolic risk factors.\n\nParticipants will\n\n* Consume the powder dissolved in water twice daily for 3 weeks\n* Follow their usual diet, modified to limit polyphenol-rich foods\n* Visit the clinic at the beginning and end of the intervention for vascular measurements and blood sample collection\n* Complete a 3-day 24-hour dietary recall and collect stool sample before each visit",[27,125,126,127,128],"Blood Pressure","Dysbiosis","Inflammation","Permeability; Increased",[130,131,132],"gut microbiome","nutrition","cardiometabolic health","2026-04-10",{"date":135,"type":41},"2026-04-13",{"date":137,"type":41},"2025-05-07",{"date":139,"type":22},"2027-01",{"name":141,"class":85},"University of California, Davis",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":116,"maxAge":58,"enrollmentInfo":149,"targetDuration":4,"studyType":120,"phases":150,"briefSummary":151,"conditions":152,"keywords":167,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":49},"100572617","wild-blueberries-for-gut-brain-and-heart-health-in-adults-with-high-blood-pressure-100572617","NCT06735599","Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure","Effects of Wild Blueberry Consumption on Gut, Brain, and Cardiovascular Health in Non-Hispanic Black and White Adults With High Blood Pressure","Inclusion Criteria:\n\n* Individuals 45-65 years of age\n* Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and\u002For diastolic blood pressure = 80-89 mmHg) for at least 6 months\n* BMI 25-35 kg\u002Fm2 via anthropometric measurements.\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of one hypertensive drug for less than three months\n* Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury\n* Smoking\n* Alcohol consumption (\\>2 drinks\u002Fday)\n* Consuming antioxidant, probiotic, and prebiotic supplements\n* Pregnant or lactating\n* Participating in a weight loss program",{"count":119,"type":22},[122],"The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.",[153,154,155,156,157,158,159,160,161,162,163,164,27,165,127,166],"Hypertension (Without Type 2 Diabetes Mellitus)","High Blood Pressure","Male","Female","Adult","Cognition","Endothelial Function (Reactive Hyperemia)","Oxidative Stress","Diet","Overweight","Body Composition Measurement","Gut Microbiome","Caucasian Whites","Microvascular Function",[168,63,162,154,169,170,171,172,173,174,175],"Blueberries","Endothelial Function","Cognitive Function","Dietary intervention","functional foods","gut microbiota","arterial stiffness","microvascular function","2026-03-23",{"date":178,"type":41},"2026-03-27",{"date":180,"type":41},"2024-09-17",{"date":182,"type":22},"2027-01-01",{"name":184,"class":85},"Georgia State University",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":192,"minAge":193,"maxAge":58,"enrollmentInfo":194,"targetDuration":4,"studyType":120,"phases":196,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":49},"100572621","wild-blueberries-for-gut-brain-and-cardiometabolic-health-in-prediabetes-100572621","NCT06735651","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Female Adults With Prediabetes.","Inclusion Criteria:\n\n* Women aged 20-65 years old\n* Prediabetes (fasting blood glucose 100-125 mg\u002FdL and\u002For HbA1c percentage between 5.7-6.4)\n* Body Mass Index between 25-30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, thyroid, stage 1 \\& 2 hypertension and other cardiovascular diseases, neurological diseases, or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n* Currently taking berry supplements or recently participated in another study taking berry supplements","FEMALE","20 Years",{"count":195,"type":22},30,[122],"The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.",[199,156,157,159,27,158,160,200,162,127,166,201],"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Gut Microbiota","Body Composition",[168,203,204,205,171,206,207,208,209,210,211,212,166,213],"Prediabetes","Insulin Resistance","Functional foods","Endothelial function","Vascular function","Cardiovascular health","Metabolic health","Gut microbiota","Cognitive function","Type II diabetes","Wild Blueberries",{"date":215,"type":41},"2026-03-25",{"date":217,"type":41},"2024-09-20",{"date":219,"type":22},"2026-06-01",{"name":184,"class":85},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100617921","the-effect-of-lipoprotein-a-on-arterial-stiffness-endothelial-function-and-myocardial-deformation-100617921","NCT07324902","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Left Atrial and Left Ventricular Deformation - An Observational Study.","Lpa_endo","Inclusion Criteria:\n\n* Adults participants 18-75 years old\n* Willing to sign the informed consent and paerticipate in the study\n\nExclusion Criteria:\n\n* History of autoimmune\u002Fautoinflammatory disease,\n* Severe valvular heart disease,\n* severe chronic kidney disease(eGFR\\\u003C60 ml\u002Fmin\u002F1.73 m2),\n* Active Pregnancy\n* Severe hepatic impairment.","75 Years",{"count":231,"type":22},300,"1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a).\n2. Purpose of the Study\n\n   The primary purpose of this study is to investigate the effect of Lp(a) levels on arterial stiffness, endothelial function, and left atrial (LA) and left ventricular (LV) deformation over a 12-month follow-up period.\n\n   Secondarily, the study will investigate:\n   * a) The incidence of major adverse cardiovascular events (MACE), including cardiovascular death, acute myocardial infarction, and acute stroke.\n   * b) The correlation between MACE incidence and parameters of arterial stiffness, endothelial function, and LA\u002FLV deformation.\n   * c) The levels of oxidative load markers.\n3. Materials and Methods This observational study will include adults aged 18-75 years (regardless of gender) who visit the outpatient clinics of the 2nd University Cardiology Clinic at \"Attikon\" General Hospital. All participants will sign a consent form. A full medical history, clinical examination, and blood collection will be performed to determine levels of Total Cholesterol, LDL-C, HDL-C, triglycerides, and Lp(a) at each visit..\n\nParticipants will be divided into three groups:\n\n* Group A: Lp(a) ≥50 mg\u002FdL with Total Cholesterol\\\u003C200 mg\u002Fdl\n* Group B : Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\>200 mg\u002Fdl\n* Group C (Control): Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\\u003C200 mg\u002Fdl At each group n ≥ 100 participants are anticipated.\n\nMeasurements at baseline, at 6 and at 12 months:\n\n* Arterial Stiffness: Determination of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP device and 24-hour pulse wave analysis with the Mobil-O-Graph device.\n* Endothelial Function: Measurement of the endothelial glycocalyx thickness of sublingual capillaries using a Sidestream Dark Field (SDF) camera (GlycoCheck). This is expressed through the perfused boundary region (PBR) index.\n* Cardiac Deformation: Use of two-dimensional strain (speckle tracking) to calculate the Global Longitudinal Strain (GLS) of the LV and LA strain.\n* Oxidative Load: Determination of malondialdehyde (MDA) and protein carbonyls (PCs) levels as markers of oxidative stress using spectrophotometric kits.\n\nStatistical Analysis: Comparisons regarding the changes in these markers over 6 and 12 months will be conducted between the three groups.",[234,27,235],"Lipoprotein Disorder","Endothelial Dysfunction",[237,238,239,240,241],"lipoprotein a","artrial stiffness","endothelial glycocalyx","myocardial deformation","oxidative stress","2026-03-10",{"date":244,"type":41},"2026-03-11",{"date":246,"type":41},"2024-09-25",{"date":248,"type":22},"2027-08-17",{"name":250,"class":85},"University of Athens",2,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":16,"sex":17,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":120,"phases":264,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":49},"100555002","phase-2-empagliflozin-reversal-of-arterial-stiffness-in-aging-100555002","NCT06506422","Empagliflozin Reversal of Arterial StiffnEss in Aging","SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging","ERASE-Aging","Inclusion Criteria:\n\n* Able to provide consent\n* 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)\n* Stable anti-hypertensive medication regimen (if in use) for at least 90 days\n* Evidence of arterial stiffening (defined as carotid-femoral PWV \\>\u002F= 8 m\u002Fs) at the time of screening visit.\n\nExclusion Criteria:\n\n* Diabetes\n* BMI\\>\u002F= 45kg\u002Fm2\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke\n* Estimated glomerular filtration rate GFR \\\u003C 29 mL\u002Fmin\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Excessive alcohol consumption (\\>14 drinks\u002Fweek for men, \\>7 drinks\u002Fweek for women)\n* Use of hormone replacement therapy\n* Body weight change ≥10% within the last 6 months\n* Uncontrolled hypertension during screening visit (\\>180\u002F110 mmHg)\n* Symptomatic hypotension and\u002For a SBP \\\u003C100 mmHg\n* History of ketoacidosis\n* High fall risk per assessment of study physician and\u002For safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements)\n* Anticipated need of prolonged fasting\n* History of recurrent UTIs or mycotic genital infections\n* Following a low-carbohydrate diet (\\\u003C20 grams\u002Fday)\n* Participation in regular exercise \\> 3 days\u002Fweek per week at a moderate or vigorous intensity\n* Known sensitivity to nitrate medications","60 Years","80 Years",{"count":263,"type":22},80,[265,266],"PHASE2","PHASE3","Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg\u002Fday for 12 weeks) reduces aging-related arterial stiffening.",[269,27],"Aging","2026-02-04",{"date":272,"type":41},"2026-02-06",{"date":274,"type":41},"2024-08-18",{"date":276,"type":22},"2029-02-28",{"name":278,"class":85},"University of Missouri-Columbia",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":192,"minAge":286,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":120,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":49},"100598383","arterial-stiffness-in-individuals-with-breast-cancer-100598383","NCT07070778","Arterial Stiffness in Individuals With Breast Cancer","The Effect of Upper Extremity Aerobic Exercise Training on Arterial Stiffness in Individuals With Breast Cancer","Inclusion Criteria:\n\n* To be between the ages of 40-69,\n* Baseline left ventricular ejection fraction (LVEF) \\>50%,\n* Absence of coronary artery disease and haemodynamically significant valvular heart disease,\n* Absence of carotid atherosclerotic plaques,\n* Volunteering to participate in the research,\n* At least 15 months after breast cancer surgery,\n* No problems in reading and\u002For understanding the scales and being able to co-operate with the tests.\n* Physically inactive (60 minutes of structured exercise per week \\\u003C).\n\nExclusion Criteria:\n\n* Presence of active infection,\n* Presence of bilateral breast cancer,\n* History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery,\n* Having a neurological disease or other clinical diagnosis that may affect cognitive status,\n* Left ventricular dysfunction and severe liver and kidney dysfunction before starting chemotherapy\n* Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease.\n* Presence of unstable hypertension or diabetes mellitus.","40 Years","69 Years",{"count":289,"type":22},18,[122],"The aim of this study was to evaluate vascular toxicity induced by anthracyclines and other anticancer drugs and to measure arterial stiffness in women with breast cancer and, in addition, to evaluate the acute and chronic arterial stiffness responses of upper extremity aerobic exercise training.",[293,294,27],"Aerobic Exercise","Breast Cancer",[296,297,27],"breast cancer","Aerobic exercise training","2025-12-25",{"date":300,"type":41},"2025-12-29",{"date":302,"type":41},"2025-07-08",{"date":304,"type":22},"2026-12-01",{"name":306,"class":85},"Hacettepe University",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":316,"conditions":317,"keywords":323,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":49},"100426841","effects-of-cross-sex-hormone-therapy-on-eating-behavior-metabolism-energy-balance-and-cardiovascular-system-100426841","NCT04838249","Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System","Investigation of the Effects of Testosterone and Estrogen on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System in Transsexual Patients Undergoing Cross-sex Hormone Therapy","HHS","Inclusion Criteria:\n\n* transsexual patients undergoing cross-sex hormone therapy versus controls\n* able to give informed consent, if \\\u003C18 years from all legal guardians\n* only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months, BMI ≤ 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.)\n* self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders (Cushing's disease, other uncontrolled pituitary disorders, uncontrolled hypothyroidism, hyperthyroidism, etc.)\n* Chronic pulmonary disorders, including chronic obstructive pulmonary disease that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome; only subjects with mild or exercise-induced asthma on no medications or on beta-adrenergic agonists only will be allowed to enter the study (provided use of these agents is not required for 1 week before\n* Diagnosed gastrointestinal diseases, including inflammatory bowel diseases (e.g. Crohn's disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active); only subjects with gastro-esophageal reflux will be allowed to enter the study entry).\n* History of HIV infection or ongoing chronic infection (such as tuberculosis)\n* only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head\u002Fneck region, claustrophobia etc.)",{"count":263,"type":22},"Current study aims to characterize five highly interconnected physiological systems in patients undergoing cross-sex hormone therapy - namely glucose and lipid metabolism, energy balance, eating behavior, functional brain networks involved in the regulation of eating behavior and the cardiovascular system - to gain novel insights into the effects of sex hormones on the human body. Gathered information will help to identify pathophysiological mechanisms for the development of overeating\u002Fobesity, insulin resistance, and cardiovascular disease. Secondarily, the relationships between the gut and oral microbiomes and metabolomes and circulating bacterial signatures will be investigated in relation to the other pervasive physiological systems.\n\nCurrent study is an observational study. The decision if the patient's request for cross-sex hormone therapy can complied with (i.e., if cross-sex hormone therapy is medically indicated) is made prior to the first contact with the study center and with the outpatients clinic for Endocrinology at the University Hospital in Leipzig. Decision ifor treatment is made according to national and international guidelines. Treatment of study participants with testosterone and estradiol\u002Fantiandrogens is not affected by the study. During the course of the study no invasive interventions are being performed.",[318,319,320,321,27,322],"Transsexualism","Transgenderism","Adiposity","Eating Behavior","Microangiopathy",[318,324,325,326,320,327],"Energy expenditure","Energy balance","Eating behavior","Cardiovascular disease","2025-11-27",{"date":330,"type":41},"2025-12-05",{"date":332,"type":41},"2021-05-05",{"date":334,"type":22},"2026-05",{"name":336,"class":85},"University of Leipzig",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":120,"phases":346,"briefSummary":347,"conditions":348,"keywords":352,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":49},"100611783","phase-2-use-of-dapagliflozin-in-primary-prevention-of-cardiotoxicity-of-anthracycline-chemotherapy-in-breast-cancer-patients-100611783","NCT07245069","Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","Alpaca","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Histologically confirmed breast cancer with planned (neo)adjuvant anthracycline-based chemotherapy (4 cycles of epirubicin + cyclophosphamide or doxorubicin + cyclophosphamide).\n* Eligible to start dapagliflozin or placebo prior to or at initiation of chemotherapy.\n* Able to perform baseline echocardiography, vascular ultrasound (FMD and carotid stiffness), 6-minute walk test, and biomarker sampling.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known heart failure (any prior diagnosis of HF).\n* Clinically significant valvular heart disease.\n* Prior exposure to chemotherapy or radiotherapy to the left chest.\n* Type 1 diabetes mellitus.\n* Symptomatic hypotension.\n* History of recurrent urinary tract infections.\n* History of diabetic ketoacidosis or ketonemia.\n* Severe hepatic impairment (ALT, AST, ALP \\>3× upper limit of normal).\n* Severe renal impairment (eGFR \\\u003C20 mL\u002Fmin\u002F1.73 m²).\n* Known allergy or intolerance to SGLT-2 inhibitors.\n* Any use of SGLT-2 inhibitor therapy within 3 months prior to enrollment.\n* Pregnancy or breastfeeding.\n* Any condition that, in the investigator's judgment, could interfere with study participation, safety, or completion.",{"count":345,"type":22},100,[265],"The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused by anthracycline chemotherapy in adult women with breast cancer receiving (neo)adjuvant treatment.\n\nThe main questions the study aims to answer are:\n\ni) Does dapagliflozin reduce the decline in left ventricular function (measured by LVEF, GLS, and myocardial work) during and after anthracycline therapy? ii) Does dapagliflozin lessen the deteriorating effect of chemotherapy on endothelial function and arterial stiffness? iii) Does dapagliflozin effect levels of cardiac injury and inflammation biomarkers (e.g., hs-troponin T, NT-proBNP, ST-2, GDF-15, galectin-3, IL-6, MPO)?\n\nResearchers will compare dapagliflozin 10 mg daily with placebo to see whether those receiving dapagliflozin experience less heart and vascular impairment during treatment.\n\nParticipants will:\n\n* Take either dapagliflozin or placebo once daily during anthracycline chemotherapy.\n* Undergo heart and vascular ultrasound, and a 6-minute walk test before chemotherapy and again at 24 and 52 weeks.\n* Provide blood samples before, during and after chemotherapy to measure cardiac biomarkers.\n* Complete multiple questionnaires on quality of life.",[349,350,351,27,294],"Heart Failure","Anthracycline-induced Cardiac Toxicity","Endothelial Function (FMD)",[353,354,294,355,356,357,358,169,359,99,360,361,349,127,362],"Anthracycline-induced cardiac toxicity","Dapagliflozin","Cardio-Oncology","Primary Prevention","Global Longitudinal Strain","Myocardial Work","Flow-Mediated Dilation","Troponin","NT-proBNP","Sodium-Glucose Transporter 2 Inhibitors","2025-11-17",{"date":365,"type":41},"2025-11-24",{"date":367,"type":41},"2025-02-01",{"date":369,"type":22},"2029-02",{"name":371,"class":85},"University Medical Centre Ljubljana",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":120,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":49},"100511747","vitamin-k2-supplementation-in-adult-episodic-migraine-100511747","NCT05943457","Vitamin K2 Supplementation in Adult Episodic Migraine","Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine","ViKEM","Inclusion Criteria:\n\n* Adults aged 18 years or above\n* History of episodic migraine with or without aura since \\> 12 months according to the ICHD-3 criteria.\n* Migraine frequency from 4-14 days per month over the 3 months prior to screening.\n* Migraine frequency from 4-14 days per month during the baseline period of assessment.\n* Successful completion of the migraine diary during the baseline evaluation period.\n\nExclusion Criteria:\n\n* Migraine patients with superimposed tension type or other forms of primary headaches\n* Patients who are currently on any of the migraine prophylactic treatments (Sodium valproate, Topiramate, Beta-blockers, Tricyclic antidepressants, SRNI, Flunarizine, Verapamil, Lisinopril, Candesartan)\n* Patients who have been on any of the previously listed medications within 3 months of screening\n* Patient who takes the following medications:\n\n  * Ergotamine or Triptans \\> 10 days per month\n  * NSAIDs or paracetamol \\> 15 days per month\n  * Opioids more than 4 days per month\n  * Patients on anticoagulants\n* Other active chronic pain syndromes (i.e. fibromyalgia, painful peripheral neuropathy, post-herpetic neuralgia…)\n* History of hypersensitivity to the vitamin K2\n* History of soy protein, cheese, eggs and meat allergy\n* History of thrombotic events\n* Diagnosed coagulopathy or any condition related to coagulation\n* Cardiovascular event in the past month\n* Current or planned pregnancy\n* Lactation\n* Inability to tolerate oral medications\n* Known intestinal malabsorption or hypomotility syndromes\n* Atrial fibrillation\n* Active malignancy\n* Any acute illness in the past month",{"count":381,"type":22},160,[122],"Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.",[385,27,386],"Migraine Headache","Vitamin K Deficiency",[388,68,389,390],"Migraine","Vitamin K deficiency","Migraine attack","2025-11-14",{"date":393,"type":41},"2025-11-18",{"date":395,"type":41},"2024-03-06",{"date":397,"type":22},"2026-12",{"name":399,"class":85},"Sola Aoun Bahous, M.D. Ph.D.",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":49},"100402630","diurnal-bp-patterns-in-those-at-increased-risk-of-cvd-100402630","NCT04522765","Diurnal BP Patterns in Those at Increased Risk of CVD","Diurnal Blood Pressure and Arterial Stiffness Patterns in Those at Increased Risk of Cardiovascular Disease","Inclusion Criteria:\n\n* Patients will be eligible to take part in the study if they attend NHS Lothian inpatient or outpatient services and can be classified as being at increased risk of CVD. This will include, but is not limited to, the following subgroups:\n\n  1. CKD as defined by the Kidney Disease Outcome Quality Initiative (K\u002FDOQI) classification\n  2. AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) classification\n  3. Small vessel vasculitis\n  4. Kidney transplant recipient\n  5. Kidney donor We will also recruit a healthy control group from the community.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\>90 years\n2. Lack of ability to provide informed consent","90 Years",{"count":409,"type":22},120,"In health, blood pressure (BP) falls at night by \\>10% compared with day-time values. This natural dipping pattern is important as without it there is an increased risk of cardiovascular disease (CVD). Recent evidence suggests that chronotherapy (taking anti-hypertensive medication at bedtime instead of in the morning) may enhance nocturnal BP dipping and reduce the risk of CVD events. There is therefore an urgent need to characterise diurnal BP patterns in patients who may be at risk of reduced nocturnal dipping in order to maximise protective therapy in all those who would benefit. Similarly, it has previously been demonstrated that increased arterial stiffness is associated with increased CVD risk, however little is known about whether loss of diurnal variations in arterial stiffness confer addition risk. Kidney disease is independently associated with increased CVD events, but the exact makeup of this risk is not clear. Within this heterogenous cohort several very distinct groups exist including those with acute kidney injury (AKI), chronic kidney disease (CKD), inflammatory conditions like small vessel vasculitis (SVV), and those who have either donated or received a kidney transplant. Diurnal BP and arterial stiffness patterns within these patient groups are not well characterised. The investigators will recruit patients at increased risk of CVD from the Royal Infirmary of Edinburgh Renal and Vasculitis Clinics. Participants will undergo 24-hour ambulatory BP and arterial stiffness measurement in conjunction with day- and night-time blood and urine sampling on two separate occasions. This study aims to characterise diurnal patterns of BP and arterial stiffness in patients at increased risk of CVD and compare findings with healthy controls. In doing so, the investigators aim to allow more targeted CVD risk reduction strategies and improve long-term patient outcomes.",[412,125,27,413],"Cardiovascular Risk Factor","Chronic Kidney Diseases","2025-09-18",{"date":416,"type":41},"2025-09-23",{"date":418,"type":41},"2020-03-17",{"date":420,"type":22},"2026-12-31",{"name":422,"class":85},"University of Edinburgh",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":16,"sex":17,"minAge":260,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":49},"100522192","risk-markers-of-arterial-aging-the-paris-prospective-study-iii-2-100522192","NCT06079424","Risk Markers of Arterial Aging. The Paris Prospective Study III-2","Risk Markers of Arterial Aging and Subsequent Risk of Cardiovascular Diseases and Beyond. The Paris Prospective Study III-2","PPS3-2","Inclusion Criteria:\n\n* Being enrolled in PPS3 and having signed an informed consent for PPS3-2\n\nExclusion Criteria:\n\n* Institutionalized participants\n* Participants under guardianship\n* Participants under judicial safeguard measure","95 Years",{"count":433,"type":22},7500,"The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.",[27],[437,438,439],"risk factors","cohort","cardiovascular diseases","2025-09-04",{"date":442,"type":41},"2025-09-11",{"date":444,"type":41},"2025-06-20",{"date":446,"type":22},"2033-12",{"name":448,"class":449},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":457,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":120,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":49},"100513442","high-intensity-exercise-to-combat-vascular-and-cognitive-dysfunction-in-adults-with-hiv-100513442","NCT05965518","High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV","A Pilot Trial of High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Older Adults With HIV","Inclusion Criteria:\n\n* Age 50 years and older\n* Sedentary lifestyle, defined as \\\u003C 150 min\u002Fwk moderate physical activity as assessed by CHAMPS questionnaire\n* Neurocognitive Impairment (as assessed using the BRACE+\n* Prescribed HIV ART for ≥ 12 months, with no current use of older drugs with established mitochondrial toxicity\n* Able to speak, read, and write in English\n* Willingness to participate in all study procedures\n\nExclusion Criteria:\n\n* Diagnosis of mitochondrial disease\n* Active substance abuse or factors preventing compliance or safety\n* Uncontrolled hypertension, defined as resting BP \\> 150\u002F90 mmHG\n* Chronic kidney disease\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Acute myocardial infarction identified by medical history and ECG\n* Pulmonary disease requiring the use of supplemental oxygen\n* Poorly controlled diabetes\n* Neuropsychologically Intact\n* Orthopedic problems that limit ability to perform exercise\n* Simultaneous participation in another intervention trial","50 Years",{"count":459,"type":22},60,[122],"This is a single site, randomized exercise trial with individuals at least 50 years of age living with HIV who experience suboptimal cognition. The overall goals of this proposal are to determine whether 16 weeks of structured high-intensity interval training (HIIT) can overcome vascular and cognitive impairments (Aim 1) to a greater extent than continuous moderate exercise. Additionally, investigator will seek to identify barriers to engagement in exercise and the participants' perceptions of the study and exercise interventions (Aim 2). This study will enroll 60 participants in Birmingham, Alabama. Data collection will occur at each visit, with baseline data collected at the initial visit with a 3-month follow-up occurring following completion of the intervention.",[463,27,464],"HIV","Cognitive Dysfunction","2025-08-04",{"date":467,"type":41},"2025-08-08",{"date":469,"type":41},"2024-02-05",{"date":471,"type":22},"2028-12",{"name":473,"class":85},"University of Alabama at Birmingham",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":483,"conditions":484,"keywords":487,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":49},"100596138","cardiovascular-risk-factors-and-physical-activity-in-chronic-kidney-patients-on-peritoneal-dialysis-100596138","NCT07041554","Cardiovascular Risk Factors and Physical Activity in Chronic Kidney Patients on Peritoneal Dialysis","Examination of Cardiovascular Risk Factors and Physical Activity in Chronic Kidney Patients Treated With Peritoneal Dialysis","Inclusion Criteria:\n\n* Diagnosed with chronic kidney disease\n* Peritoneal dialysis treatment for at least three months\n* Age ≥ 18\n\nExclusion Criteria:\n\n* Mini Mental Test Score \\\u003C 24\n* Serious cardiovascular, pulmonary, or neurological conditions that make it impossible to wear an accelerometer\n* Inability to walk independently\n* Conditions affecting participation in daily life due to lower limb injury or surgery",{"count":482,"type":22},23,"The objective of this study was to examine the association between cardiovascular risk factors and physical activity parameters in patients with chronic kidney disease who are treated with peritoneal dialysis.",[413,485,27,486],"Cardiovascular Risk Factors","Physical Activity",[488,489,174,490,491],"cardiovascular risk factors","physical activity","accelerometer","peritoneal dialysis","2025-06-18",{"date":494,"type":41},"2025-06-27",{"date":496,"type":22},"2025-06-23",{"date":498,"type":22},"2025-12-31",{"name":500,"class":85},"Dokuz Eylul University",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":16,"sex":17,"minAge":507,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":49},"100593020","scapis-2-cardio---vibrometer-based-pulse-wave-analysis-and-cvd-risk-assessment-100593020","NCT07001007","SCAPIS 2 Cardio - Vibrometer Based Pulse Wave Analysis and CVD Risk Assessment","Inclusion Criteria:\n\n* Subjects already included in the main \u002F general SCAPIS 2 study at Danderyd Hospital in Stockholm, and of which has also participated in the echocardiography examination\n\nExclusion Criteria:\n\n* Patients unable to provide an informed consent","58 Years","72 Years",{"count":510,"type":22},1600,"This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and pulse wave characteristics and explore its potential in assessment of coronary artery disease, aortic stenosis and heart failure, in a population-based sample aged 58-72 years.\n\nIt will be the first in clinical setting, pilot stage, observational investigation to evaluate the clinical safety, performance and diagnostic accuracy of Cardio P4, a laser-doppler vibrometry (LDV) and microwave radar-based device.",[513,27,514,349],"Coronary Arterial Disease (CAD)","Aortic Valve Disease","2025-05-30",{"date":517,"type":41},"2025-06-03",{"date":519,"type":41},"2024-07-01",{"date":521,"type":22},"2026-06",{"name":523,"class":524},"HJN Sverige AB\u002FNeko Health","INDUSTRY",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":531,"maxAge":18,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":534,"conditions":535,"keywords":540,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":49},"100451542","early-detection-of-long-term-diabetic-complications-in-children-and-adolescents-with-type-1-diabetes-100451542","NCT05159856","Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes","Inclusion Criteria:\n\n* T1D\\>12 months\n* 6-18 years old prior to inclusion\n* Followed at the Pediatric Diabetes outpatient clinic at Steno Diabetes Center Copenhagen\n* Speaks and reads Danish well enough to understanding the given oral and written information.\n* There is a written consent from the guardianship holder\u002Fholders for the child.\n\nExclusion Criteria:\n\n* T1D \\\u003C 12 months\n* Known cardiovascular disease\n* Antihypertensive treatment","6 Years",{"count":533,"type":22},400,"Aims: To investigate early markers of long-term diabetic complications and the association to an extended glucose metabolic profile comprising glucose control (current and past), glucose variability and insulin sensitivity in children and adolescents with type 1 diabetes (T1D).\n\nBackground: Most Danish children and adolescents with T1D do not achieve their metabolic target and are at increased risk of developing long-term diabetic complications, reducing their life expectancy and increase their morbidity rate. Hence, improved metabolic control, a better understanding of what optimal metabolic control means, combined with detailed monitoring of the first markers of long-term complications and their reversibility or lack thereof are needed.\n\nMethods: A prospectivel study of 400 children, aged 6-18 years old, with T1D\\>12 months. Early markers of long-term diabetic complications will be investigated as arterial stiffness, nerve dysfunction and nephropathy. Data on T1D onset, duration, treatment modality, self-monitoring-blood-glucose profiles, growth, weight, and pubertal status will be collected.\n\nBlood sampling will include routine tests and markers of glucose, lipid, bone, and gastrointestinal metabolism. DXA-scan, Fibroscan, bone-age, eye-examination and physical activity will be measured. Data on retrospective glucose- and lipid-profiles will be collected. The children will be offered a followup every 5 years for the next two decades.\n\nPerspectives: This study provides novel insight into the frequency of early markers of long-term diabetic complications and its association to the interplay of the pancreas, adipose, gastrointestinal and bone metabolic axis. Which can assist in identifying subgroups of children and adolescents requiring earlier in-depth screening for early markers of long-term diabetic complications, for putative interventions for prevention, hence reducing morbidity and mortality in T1D.",[536,537,538,539,27],"Diabetes Complications","type1diabetes","Children, Only","Diabetic Neuropathies",[541,542,543,544,545,546],"pediatric","arteriel stiffness","pulse wave velosity","neuropathy","type 1 diabetes","early diabetic complications","2025-05-28",{"date":517,"type":41},{"date":550,"type":41},"2022-05-03",{"date":552,"type":22},"2025-12",{"name":554,"class":85},"Steno Diabetes Center Copenhagen",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":192,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":575,"locationsCount":49},"100422651","early-prediction-of-preeclampsia-using-arterial-stiffness-in-high-risk-pregnancies-100422651","NCT04783597","Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies","Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies; a Multinational Study (PULSE)","PULSE","Inclusion Criteria:\n\n* Singleton pregnancy\n* Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia\n\nExclusion Criteria:\n\n* \\>14 weeks gestation\n* Multiple pregnancy\n* History of heart disease, stroke, or peripheral arterial disease\n* Infectious diseases\u002Fconditions, such as Hepatitis B\u002FC, HIV, and COVID19",{"count":564,"type":22},2400,"Despite advances in obstetric care, preeclampsia (PE) remains the leading cause of maternal death and disability in both developed and developing countries, contributing to over 70,000 maternal and 500,000 fetal deaths annually worldwide. PULSE was designed using a preventative medicine approach, focusing on improving early detection of PE as opposed to managing symptoms after onset. The study aims to uncover the earliest possible signs of PE using a combination of novel clinical tools and established diagnostic techniques to better identify, track, and manage high risk pregnant women. Specifically, PULSE will be examining the incorporation of a non-invasive test for the measurement of arterial stiffness, which has been shown to be predictive of hypertensive disorders. This test, in combination with a wide range of blood biomarkers, detailed ultrasound imaging, and a comprehensive battery of physical and mental health questionnaires, represents the largest, most comprehensive preventative PE study to date. The results of this work has the potential to revolutionize the way PE and other hypertensive disorders of pregnancy are managed and treated and can serve to inform the design of future preventative clinical research studies.",[567,27,568],"High Risk Pregnancy","Pre-Eclampsia","2025-04-15",{"date":571,"type":41},"2025-04-18",{"date":573,"type":41},"2021-07-12",{"date":139,"type":22},{"name":576,"class":85},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":584,"targetDuration":4,"studyType":120,"phases":586,"briefSummary":588,"conditions":589,"keywords":594,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":608,"leadSponsor":610,"locationsCount":49},"100586448","phase-4-shenfu-injection-modulates-carotid-elasticity-in-septic-shock-100586448","NCT06915506","Shenfu Injection Modulates Carotid Elasticity in Septic Shock","The Effect of Shenfu Injection on Carotid Artery Elasticity in Septic Shock Patients: A Prospective Observational Pilot Study","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Diagnosis of sepsis or septic shock in the acute phase, as defined by the -Sepsis-3 criteria (confirmed infection with Sequential Organ Failure Assessment \\[SOFA\\] score ≥ 2 points above baseline).\n* Voluntary participation with written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria\n\n* Severe carotid atherosclerosis (e.g., carotid Intima-Media Thickness (IMT)\\>1.2 mm or confirmed plaque formation) diagnosed by prior imaging.\n* Significant cardiovascular comorbidities that may confound hemodynamic assessments, including:\n* Severe cardiomyopathy (e.g., ejection fraction \\\u003C30%).\n* Uncontrolled arrhythmias (e.g., ventricular tachycardia, atrial fibrillation with rapid ventricular response).\n* Congenital heart disease with hemodynamic instability.\n* Active hepatic or renal insufficiency (e.g., Child-Pugh class C, dialysis dependence) or advanced systemic diseases (e.g., metastatic malignancy, terminal illness).\n* Poor ultrasound image quality precluding reliable speckle tracking analysis (e.g., inadequate acoustic window, motion artifacts).\n* Pregnancy or lactation (due to potential hormonal influences on vascular physiology).\n* Withdrawal from the study or inability to complete follow-up assessments (e.g., non-compliance, transfer to another facility).",{"count":585,"type":22},48,[587],"PHASE4","What is this study about? We are studying whether Shenfu Injection (a traditional Chinese herbal medicine) can help improve blood vessel health in patients with septic shock-a severe complication of infections that can damage blood vessels and organs. Specifically, we want to see if this treatment makes the carotid artery (a major neck blood vessel) more flexible and resilient, which may support recovery.\n\nWho can join? Adults (18 years or older) diagnosed with septic shock by their doctors. Patients whose doctors plan to use Shenfu Injection as part of their treatment. Patients who agree to participate and sign a consent form. Who cannot join? Patients with severe heart conditions, advanced organ failure, or major neck artery disease.\n\nPregnant or breastfeeding women. Those unable to complete the study procedures. What will happen during the study?\n\nSafe and Pain-Free Tests:\n\nUltrasound scans: A non-invasive imaging method will be used to measure the flexibility and blood flow of your neck artery.\n\nAdvanced imaging technology: A special ultrasound technique (called speckle tracking) will take detailed pictures of your artery's movement during heartbeat cycles.\n\nTiming of Tests:\n\nScans will be done before receiving Shenfu Injection and 1, 2, 3 hours after the injection, plus 1 hour after treatment ends.\n\nOther Data Collection:\n\nBlood tests to check inflammation and organ function. Recording your health status (e.g., blood pressure, heart rate) and recovery progress (e.g., time in the Intensive Care Unit (ICU), survival rates).\n\nWhat are the benefits and risks? Benefits: This study may help doctors better understand how Shenfu Injection works and improve future care for septic shock patients.\n\nRisks: The ultrasound scans are routine, safe, and painless. There is no extra risk beyond standard hospital care.\n\nYour Rights and Safety Voluntary Participation: You can withdraw at any time without affecting your treatment.\n\nEthical Approval: This study is reviewed and approved by the hospital's ethics committee.\n\nPrivacy: Your personal information and test results will be kept confidential.",[590,591,27,592,593],"Septic Shock","Vascular Dysfunction","Carotid Artery Elasticity Alterations","Sepsis",[595,596,597,598,599,68,600,601,602,603],"Septic shock","Shenfu Injection","Carotid artery elasticity","Ultrasound speckle tracking","Vascular dysfunction","Strain imaging","Traditional Chinese Medicine (TCM)","Circumferential strain (CS)","Sepsis-associated vascular injury","2025-04-04",{"date":606,"type":41},"2025-04-08",{"date":569,"type":22},{"date":609,"type":22},"2026-04-30",{"name":611,"class":85},"First Affiliated Hospital of Wannan Medical College",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":49},"100584179","the-effect-of-cytisine-treatment-for-smoking-cessation-on-cardiovascular-function-in-adult-smokers-100584179","NCT06885970","The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers","The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers of Conventional Combustible Cigarettes and New Tobacco Products-Observational Study.","Cytisin-angio","Inclusion Criteria:\n\n* Smokers willing to participate\n\nExclusion Criteria:\n\n* history of coronary artery disease, active malignancy, history of severe liver and renal failure, history of autoimmune disease.",{"count":621,"type":22},200,"Introduction: Pharmacological interventions can enhance smoking cessation success and long-term abstinence. Cytisine, a plant derived alkaloid, is a selective partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors, which are crucial in nicotine dependence.\n\nAim of the Study The primary objective of this observational study is to evaluate the efficacy of cytisine in a standard 25-day dosing regimen among adult smokers and users of alternative nicotine products (e-cigarettes or heated tobacco). The study will assess the impact of cytisine on cardiovascular function, including arterial stiffness, cardiac deformation, and endothelial glycocalyx integrity.\n\nThe secondary aim is to determine relapse rates post-treatment, treatment side effects, and new cardiovascular events during the treatment period and at six-month follow-up.\n\nMaterials and Methods: This observational study will recruit smokers visiting the smoking cessation unit at the 2nd Department of Cardiology, Attikon University Hospital, Athens. All participants will receive counseling and treatment from the attending physician.\n\nA minimum of 200 participants will be enrolled, categorized into:\n\n• At least 50 receiving cytisine in the standard dosing regimen: Days 1-3: 1 tablet every 2 hours (6 tablets daily) Days 4-12: 1 tablet every 2.5 hours (5 tablets daily) Days 13-16: 1 tablet every 3 hours (4 tablets daily) Days 17-20: 1 tablet every 5 hours (3 tablets daily) Days 21-25: 1-2 tablets daily\n\n* At least 50 receiving nicotine replacement therapy\n* At least 50 receiving prolonged cytisine therapy (3 mg, three times daily for 12 weeks)\n* At least 50 who do not intend to quit smoking (control group)\n\nAssessments will be conducted at baseline, one month, and six months post-recruitment. The following measurements will be performed:\n\nA. Arterial Stiffness: Pulse wave velocity (cf-PWV) using the Complior device to measure arterial stiffness, Augmentation index and pulse wave velocity using the Arteriograph device via brachial artery cuff.\n\nB. Endothelial Glycocalyx Integrity: Perfused boundary region (PBR) assessment of sublingual microvasculature using a Sidestream Dark Field (SDF) camera.\n\nC. Cardiac Function: Left ventricular ejection fraction (LVEF), myocardial strain (GLS), and myocardial work assessment via speckle-tracking echocardiography (Echopac 203, GE Horten Norway).The investigators will also calculate myocardial work (MW) using pressure-strain loop analysis.\n\nD. Oxidative Stress: Plasma malondialdehyde (MDA) and protein carbonyl (PC) levels measured via spectrophotometry.\n\nE. Smoking Cessation Monitoring: Exhaled carbon monoxide (CO) measured using a commercial device (Smokelyzer, Bedfont Scientific Ltd.).\n\nThis study aims to provide valuable insights into cytisine's effectiveness in smoking cessation and its impact on cardiovascular health.",[624,27,235],"Smoking Cessation",[174,626,240,239],"smoking cessation","2025-03-27",{"date":629,"type":41},"2025-04-02",{"date":631,"type":41},"2024-11-12",{"date":633,"type":22},"2025-08-10",{"name":250,"class":85},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":261,"enrollmentInfo":642,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":643,"conditions":644,"keywords":647,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":49},"100533338","pulse-wave-velocity-and-in-subacute-stroke-patients-following-rehabilitation-100533338","NCT06224517","Pulse Wave Velocity and in Subacute Stroke Patients Following Rehabilitation","The Improvement in Pulse Wave Velocity and Its Correlation With Clinical Outcomes in Subacute Stroke Patients Following Rehabilitation","Inclusion Criteria:\n\n* First-onset cerebral ischemic stroke within the previous 3 months, which is confirmed clinically by computed tomography scans or magnetic resonance imaging\n* Sufficient cognition to understand procedures and provide informed consent.\n\nExclusion Criteria:\n\n* Hemorrhagic stroke, cerebellar or brainstem lesions which may affect autonomic or balance\n* Concurrent neurological or neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis, etc.)\n* Brain tumor\n* Malignancy\n* Limb deficiency or amputation",{"count":7,"type":22},"Currently, the literature regarding the relationship between Pulse Wave Velocity (PWV) and functional recovery, particularly of upper limb function, in patients with subacute stroke is still limited. Therefore, the aim of the study is to evaluate the changes in baPWV after four weeks of intensive rehabilitation therapy, and the correlation between these changes and functional recovery.",[645,27,99,646],"Ischemic Stroke","Rehabilitation",[648,27,649,650],"ischemic stroke","pulse wave velocity","rehabilitation","2025-02-23",{"date":653,"type":41},"2025-02-25",{"date":655,"type":41},"2024-02-01",{"date":657,"type":22},"2025-06-30",{"name":659,"class":85},"Shin Kong Wu Ho-Su Memorial Hospital",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":668,"enrollmentInfo":669,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":670,"conditions":671,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":251},"100417821","bioimpedence-and-arterial-function-monitoring-at-birth-and-in-infants-100417821","NCT04720690","Bioimpedence and Arterial Function Monitoring at Birth and in Infants","Bioimpedence and Arterial Function Monitoring at Birth and in Infants: the BAMBI Study","BAMBI","Inclusion Criteria:\n\n* Healthy term infants (including those with SGA+\u002F-FGR) in the postnatal ward\n* Term and Preterm infants (including those with SGA+\u002F-FGR) admitted to the neonatal unit\n* Written informed parental consent\n\nExclusion Criteria:\n\n* Antenatal or postnatal diagnosis of complex\u002Flife-limiting congenital anomaly or genetic condition\n* Infants with no realistic chance of survival\n* Infants with fragile skin not permitting use of cuffs for research purposes\n* Babies whose parents have a limited understanding of English will be excluded in the event that communication via NHS translation services is not possible due to clinical demands on these services","6 Months",{"count":409,"type":22},"Babies may be born appropriately grown for gestational age (AGA, \\>10th centile) or small for gestational age (SGA, \\\u003C10th centile). Babies who are SGA and have evidence in utero of vascular compromise using antenatal doppler indices are classified as having fetal growth restriction (FGR). Babies with FGR are at increased risk of cardiovascular disease in adult life. Increased arterial stiffness and intima-media thickness are thought to mediate this risk in adults. It is not known how early in life these changes can be robustly detected. In addition, very little is known generally about how babies' hearts and arteries change in structure and function over the first year of life, whether affected by SGA or not. This study aims to understand if there are differences in cardiac and arterial structure and function between babies born AGA or SGA. Within the group of SGA babies, the study team will investigate whether FGR and maternal pre-eclampsia influence these measurements. The effects gestational age on these parameters will be studied within all groups: half of the babies recruited will be \\\u003C32 weeks gestational age (GA), and half will be ≥32 weeks GA. Study participants will have further measurements at 3-6 months of life to assess if cardiac and arterial structure and function change in babies over the first year of life. The study team will use the Vicorder device to measure arterial stiffness, and assess the feasibility of using this device in neonates. The Vicorder will also be used to measure cardiac output. The feasibility and validity of this device for this purpose will be investigated (Vicorder is not validated for cardiac output measurement in infants). Vicorder cardiac output results will be compared to echocardiography and bioimpedence technology (using the NICaS monitor). The study team will use ultrasound for arterial structure measurements of the carotid artery and aorta.",[27,672,673,568],"Fetal Growth Retardation","Small for Gestational Age at Delivery","2024-07-26",{"date":676,"type":41},"2024-07-29",{"date":678,"type":41},"2020-12-01",{"date":680,"type":22},"2024-12-31",{"name":682,"class":85},"Imperial College Healthcare NHS Trust",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":689,"eligibilityCriteria":690,"healthyVolunteers":16,"sex":17,"minAge":457,"maxAge":4,"enrollmentInfo":691,"targetDuration":4,"studyType":120,"phases":693,"briefSummary":694,"conditions":695,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":698,"lastUpdatePostDateStruct":699,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":4},"100549923","physical-activity-and-cardiovascular-risk-100549923","NCT06440369","Physical Activity and Cardiovascular Risk","Effets d'un Programme d'Exercice aérobie Sur cycloergomètre Chez le Patient Atteint d'Insufisance Rénale Chronique ou Polyarthrite Rhumatoïde","PACaR","Inclusion Criteria:\n\n* Healthy subject (man or woman) over 50 years old, without diagnosis of chronic disease.\n* Patient (man or woman) over 50 years old, with a diagnosis of CKD or RA without other risk factors related to the disease.\n* Have a medical certificate of no contraindication to AP.\n* Have a glomerular filtration rate between 45 and 29 ml\u002Fmin\u002F1.73 m2, corresponding to non-dyalized stages III and IV for patients with CKD.\n* Have a DAS-28 score ≥ 2.6 points for patients with RA.\n* Signature of informed consent.\n* Affiliation to a French social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* unstabilized corticosteroid therapy and\u002For \\>10 mg of prednisone\u002Fday;\n* unbalanced high blood pressure;\n* pregnant women ;\n* alteration of higher functions making understanding and adherence to a conditioning program impossible;\n* inability to perform physical exercise, whatever the origin (neurological, central or peripheral, cardiac, vascular or respiratory or musculoskeletal).\n* Legal incapacity or limited legal capacity\n* Subject unlikely to cooperate in the study and\u002For low cooperation anticipated by the investigator\n* Subject without health insurance\n* Subject being in the period of exclusion from another study or provided for by the \"national volunteer file\".",{"count":692,"type":22},105,[122],"Physical activity (PA) is essential for the prevention and treatment of chronic conditions. Despite its benefits, global physical inactivity is prevalent, contributing to chronic diseases and premature mortality. For patients with chronic kidney disease (CKD) and rheumatoid arthritis (RA), PA is particularly beneficial as it improves endothelial health, reduces cardiovascular risk, diminishes inflammation, and enhances quality of life. Given the chronic inflammation and immune system dysregulation in CKD and RA, PA may mitigate these effects and improve patient outcomes. The primary objective of this study is to evaluate the effects of a personalized aerobic exercise program on cardiovascular risk in patients with CKD or RA. The secondary objectives are to assess the effects on inflammation and immunosenescence; investigate the relationship between inflammation, immunosenescence, and various health outcomes; compare the impacts of chronic PA and PA guidance on cardiovascular risk, disease activity, lifestyle habits, cognitive functions, and quality of life.\n\nThis study presents an interventional design. A total of 105 subjects are expected to participate in this study, including 45 CKD patients and 45 RA patients. Participants will be stratified by PA level and cardiovascular risk (SCORE 2 scale) and then randomized into three groups: Control Group: 15 CKD and 15 RA patients; Therapeutic Education Group: 15 CKD and 15 RA patients; and Experimental Group: 15 CKD and 15 RA patients.\n\nThe inclusion criteria are: age \\> 50 years; diagnosed with CKD or RA; glomerular filtration rate between 45 and 29 ml\u002Fmin\u002F1.73 m² for CKD; DAS-28 score ≥ 2.6 for RA; medical clearance for PA; informed consent and affiliation with French social security. The exclusion criteria are: unstable corticosteroid therapy or \\>10 mg prednisone\u002Fday; uncontrolled hypertension; pregnancy; cognitive impairment preventing adherence to the program; inability to perform PA; legal incapacity or anticipated poor cooperation; lack of health insurance and participation in an incompatible study.\n\nThe primary efficacy criterion of this study is changes in endothelial function (macrovascular arterial stiffness) and the secondary efficacy criteria are: endothelial function (microvascular hyperemia test); levels of inflammation and immunity (blood tests); physical activity levels and quality of life (questionnaires); disease-related functional impairment; disease activity and cognitive function.\n\nPatient screening will begin with the identification of eligible patients in the Nephrology and Rheumatology departments. Day 0 will be the selection visit for participant information and consent. A week after Day 0, the inclusion visit and initial assessment (arterial stiffness, endothelial function, disease impact, and blood markers for immunosenescence and inflammation, blood pressure, heart rate, PA level, quality of life, and cognitive functions) will be conducted for all patients. Next, only the patients in the experimental group will carry out a 47-minute cycling intermittent exercise session, perceived exertion assessment, and post-exercise reassessment. They will redo the assessments after the exercise. They will have another 16 sessions of supervised exercise by a health professional and a final session identical to the first for reassessment. Patients in the physical activity guidance group will not undertake a physical exercise program but will receive one call per week to discuss the physical activities performed and get answers to their questions on the subject. The control group will continue with their usual lifestyle habits.",[696,413,235,27,697],"Rheumatoid Arthritis","Exercise","2024-06-04",{"date":700,"type":41},"2024-06-05",{"date":702,"type":22},"2024-09-01",{"date":704,"type":22},"2026-12-30",{"name":706,"class":85},"University of Franche-Comté",{"id":708,"slug":709,"hasResults":12,"nctId":710,"briefTitle":711,"officialTitle":712,"acronym":4,"eligibilityCriteria":713,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":714,"enrollmentInfo":715,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":717,"conditions":718,"keywords":719,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":730,"locationsCount":49},"100412107","the-role-of-glycocalyx-integrity-in-the-primary-prevention-of-major-cardiovascular-events-100412107","NCT04646252","The Role of Glycocalyx Integrity in the Primary Prevention of Major Cardiovascular Events","Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6 Year Follow up Study","Inclusion Criteria:\n\nWe recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital.\n\nExclusion Criteria:\n\n* History of Coronary artery disease,\n* History of Peripheral Arterial Disease,\n* History of Heart failure\n* History of Stroke\n* hepatic failure\n* renal failure,\n* active neoplasia\n* poorly controlled DM, defined as Hba1C\\>7%","85 Years",{"count":716,"type":22},500,"The researchers intend to recruit individuals who are referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital, Athens According to institutional protocols, a detailed medical history for atherosclerotic risk factors and current medication is recorded and a baseline clinical examination is performed. Moreover fasting blood samples are drawn to diagnose the presence of diabetes mellitus and hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are revaluated at one month and then followed up according to the attending physician's instructions. Pulse wave velocity and the rest pulse wave analysis parameters were also calculated to determine the additive predictive value for cardiovascular events beyond SCORE2. All subjects are followed up for adverse events (death, stroke, myocardial infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic contact and planned appointment at the outpatient clinic.",[235,27],[720,721,722],"perfused boundary region","primary prevention of major cardiovascular events","integrity of endothelial glycocalyx","2024-05-28",{"date":725,"type":41},"2024-05-29",{"date":727,"type":41},"2013-01-10",{"date":729,"type":22},"2027-05-28",{"name":250,"class":85}]